🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 77 of 116

  1. XTX202

    Xilio Therapeutics

    Advanced Solid Tumor

    phase 2 small molecule completed

    1 trial

  2. XTX301

    Xilio Therapeutics

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  3. Xeloda 150 mg film-coated tablets, ELOXATINE 5 mg/ml, solution à diluer pour perfusion, Folinic acid (as calcium folinate) 10 mg/ml solution for injection/infusion, ELVORINE 100 mg/10 mL, solution injectable, FLUOROURACILE TEVA 1000 mg/20 ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    colon cancer

    phase 2 small molecule active

    1 trial

  4. Xeloda 150 mg film-coated tablets, Folinic acid (as calcium folinate) 10 mg/ml solution for injection/infusion, ELOXATINE 5 mg/ml, solution à diluer pour perfusion, Vectibix 20 mg/ml concentrate for solution for infusion, FLUOROURACILE TEVA 1000 mg/20 ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    metastatic colorectal adenocarcinoma

    phase 2 small molecule active

    1 trial

  5. Xeloda 150 mg film-coated tablets, Xeloda 500 mg film-coated tablets, Paclitaxel 6 mg/mL concentrate for solution for infusion, Herceptin 150 mg powder for concentrate for solution for infusion, GEMZAR 200 mg, poudre pour solution pour perfusion, HALAVEN 0.44 mg/ml solution for injection, Vinorelbine 10 mg/ml concentrate for solution for infusion, GEMZAR 1000 mg, poudre pour solution pour perfusion, evorpacept, HALAVEN 0.44 mg/ml solution for injection

    ALX ONCOLOGY HOLDINGS INC

    Breast Cancer

    phase 2 small molecule active

    1 trial

  6. Xofigo 1100 kBq/mL solution for injection, DELTACORTENE 5 mg compresse, Decadron “4 mg/1 ml Soluzione iniettabile”, Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, SOLDESAM 0,2% gocce orali, soluzione

    Istituto Gentili S.r.l.

    metastatic castration resistant prostate cancer (mCRPC), symptomatic bone-only metastatic castration resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  7. Xospata 40 mg film-coated tablets

    Fondazione Telethon ETS

    newly diagnosed non-M3 FLT3-positive acute myeloid leukemia

    phase 2 small molecule active

    1 trial

  8. YERVOY 5 mg/ml concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KIMMTRAK 100 micrograms/0.5 mL concentrate for solution for infusion, DACARBAZINE

    Immunocore Ireland Limited

    Previously untreated advanced uveal melanoma (UM)

    phase 2 small molecule active

    1 trial

  9. YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.

    The George Institute

    melanoma brain metastases

    phase 2 small molecule active

    1 trial

  10. YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Disc Medicine

    castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  11. Yondelis 1 mg powder for concentrate for solution for infusion, DOXORUBICINE ARROW 2 mg/ml, solution pour perfusion

    Ningbo Cancer Hospital

    Localized, resected, FIGO stage I (2018 classification), uterine leiomyosarcoma

    phase 2 small molecule active

    1 trial

  12. Z650

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  13. ZD6474

    United Therapeutics Europe Ltd

    Lung Cancer

    phase 2 small molecule completed

    2 trials

  14. ZENGAC “500 mg Polvere per soluzione per infusione e per uso orale”, Plenvu, polvere per soluzione orale, SELG ESSE polvere per soluzione orale, Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, Vancomicina Mylan 500 mg polvere per soluzione per infusione

    Istituto Gentili S.r.l.

    unresectable hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  15. ZEULIDE 3,75 mg, poudre et solvant pour suspension injectable à libération prolongée, Elacestrant

    The George Institute

    Breast cancer

    phase 2 small molecule active

    1 trial

  16. ZG005

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd

    Biliary Tract Carcinoma

    phase 2 small molecule active

    1 trial

  17. ZIMBERELIMAB

    Arcus Biosciences

    Pancreatic Cancer

    phase 2 small molecule on hold

    1 trial

  18. ZIO-201

    Alaunos Therapeutics

    Advanced Sarcoma

    phase 2 small molecule completed

    1 trial

  19. ZIV-Aflibercept

    Regeneron UK Limited

    Metastatic Uveal Melanoma

    phase 2 small molecule active

    1 trial

  20. ZN-d5 ZN-c3

    Zentalis Pharmaceuticals

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule terminated

    1 trial

  21. ZW25 (Zanidatamab)

    Jazz Pharmaceuticals Ireland Limited

    HER2+/HR+ Breast Cancer

    phase 2 small molecule completed

    1 trial

  22. ZW25 (Zanidatamab)

    Jazz Pharmaceuticals Ireland Limited

    HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  23. ZW25 (Zanidatamab)

    BEONE MEDICINES AUS PTY LTD

    HER2-amplified Biliary Tract Cancers

    phase 2 small molecule completed

    1 trial

  24. Zanidatamab

    Jazz Pharmaceuticals Ireland Limited

    HER2-positive Breast Cancer

    phase 2 small molecule active

    1 trial

  25. Zanidatamab

    Jazz Pharmaceuticals Ireland Limited

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  26. Zanidatamab

    ALX ONCOLOGY HOLDINGS INC

    HER2-expressing Cancers

    phase 2 small molecule completed

    1 trial

  27. Zanidatamab

    Jazz Pharmaceuticals Ireland Limited

    Breast Cancer

    phase 2 small molecule active

    1 trial

  28. Zanidatamab

    Jazz Pharmaceuticals Ireland Limited

    Gastroesophageal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  29. Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    Relapsed/Refractory Follicular Non-Hodgkin Lymphoma

    phase 2 small molecule completed

    1 trial

  30. Zanubrutinib

    The First People's Hospital of Lianyungang

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  31. Zanubrutinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  32. Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    Relapsed Diffuse Large B-cell Lymphoma

    phase 2 small molecule completed

    1 trial

  33. Zanubrutinib

    The First People's Hospital of Lianyungang

    Non Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  34. Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    Follicular Lymphoma

    phase 2 small molecule active

    1 trial

  35. Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  36. Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 2 small molecule completed

    1 trial

  37. Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    Chronic Lymphocytic Leukemia (CLL)

    phase 2 small molecule active

    1 trial

  38. Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    Diffuse Large B-cell Lymphoma (DLBCL)

    phase 2 small molecule active

    1 trial

  39. Zanubrutinib+Rituximab+Lenalidomide

    The First People's Hospital of Lianyungang

    Diffuse Large B Cell Lymphoma

    phase 2 small molecule active

    1 trial

  40. Zanubrutinib, Fludarabine, cyclophosphamide and rituximab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  41. Zarzio 30 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Gilteritinib, ARA-cell® 40 mg Injektion 20 mg/ml Injektionslösung / Konzentrat zur Herstellung einer Infusionslösung, Gilteritinib, Bendarabin 50 mg Pulver zur Herstellung einer Injektions- oder Infusionslösung, Citarabina Hikma 1 g/10mL Soluzione Iniettabile

    Astellas Pharma GmbH

    FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  42. Zejula 100 mg film-coated tablets, Zejula 100 mg film-coated tablets

    GlaxoSmithKline

    Neoplasms

    phase 2 small molecule active

    1 trial

  43. Zejula 100 mg hard capsules, Zejula 100 mg film-coated tablets, JEMPERLI 500 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    metastatic or recurrent endometrial or ovarian carcinosarcoma

    phase 2 small molecule active

    1 trial

  44. Zelenectide Pevedotin, BT8009

    BICYCLE THERAPEUTICS

    Advanced or Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  45. Zelvina 10 mg hard capsules, Zelvina 25 mg hard capsules, MINJUVI 200 mg powder for concentrate for solution for infusion, Zelvina 5 mg hard capsules

    Incyte

    Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 small molecule active

    1 trial

  46. Zentalis

    Zentalis Pharmaceuticals

    Advanced Pancreatic Adenocarcinoma

    phase 2 small molecule active

    1 trial

  47. Zercepac 150 mg powder for concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Gemcitabin-GRY 1000 mg Pulver zur Herstellung einer Infusionslösung, Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    The George Institute

    cholangiocarcinoma or gallbladder carcinoma

    phase 2 small molecule active

    1 trial

  48. Ziftomenib

    Kura Oncology

    Advanced Malignant Neoplasm

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.